Conveying Value of Accelerated Approval Drugs May Be Challenge for Pharma Firms
That is the title of an article in Spotlight on Market Access published by MMIT Radar. The article examines how FDA decisions to expedite getting treatments to market will be received by payers. The Healthcare Economist is quoted extensively in the article: Payers have two key concerns, maintains Jason Shafrin, Ph.D., senior director of policy…